Abstract
Objective We investigated 36-year body mass index (BMI) trajectories in twins whose BMI in young adulthood was below, within, or above their genetically expected BMI, with a focus on twin pairs with large intrapair BMI differences (within-pair ΔBMI ≥ 3 kg/m2).
Methods Together, 3227 like-sexed twin pairs (34% monozygotic [MZ]) were examined at age ∼30 in 1975 and followed up in 1981, 1990, and 2011. In 1975, the observed BMI of an individual was considered either within (±2.0 kg/m2), below (<-2.0 kg/m2), or above (>+2.0 kg/m2) genetically expected BMI, measured by a polygenic risk score of 996,919 single nucleotide polymorphisms.
Results In MZ and DZ twin pairs with large intrapair BMI differences, the co-twin with a higher observed BMI in 1975 deviated above expected BMI more frequently (∼2/3rd) than the co-twin with a lower BMI deviated below expectation (∼1/3rd). Individuals below, within, and above expectation in 1975 reached, respectively, normal weight, overweight, and obesity by 2011, with a mean BMI increase of 4.5 (95% confidence interval 4.3 to 4.8) kg/m2.
Conclusion Categorizing BMI as below, within, or above PRS-predicted BMI helps identifying individuals who have been resistant or susceptible to weight gain. This may provide new insights into determinants and consequences of obesity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Academy of Finland (JK: 263278, 264146, 265240, 308248, 312073, 336823, 352792; KHP: 272376, 266286, 314383, 335443), the Wellcome Trust Sanger Institute (JK), the Broad Institute (JK), ENGAGE – European Network for Genetic and Genomic Epidemiology (JK: FP7-HEALTH-F4-2007, 201413), Finnish Medical Foundation (KHP), Finnish Diabetes Research Foundation (KHP), Novo Nordisk Foundation (KHP: NNF10OC1013354, NNF17OC0027232, and NNF20OC0060547), Gyllenberg Foundation (KHP), Sigrid Juselius Foundation (JK and KHP), Helsinki University Hospital Research Funds (KHP), Jalmari and Rauha Ahokas Foundation (KHP), Finnish Foundation for Cardiovascular Research (KHP), Government Research Funds (KHP), Helsinki University Hospital (KHP), and the University of Helsinki (KHP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Hjelt Institute, University of Helsinki and the ethics committee of the Helsinki and Uusimaa Hospital District gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: The study was supported by the Academy of Finland (JK: 263278, 264146, 265240, 308248, 312073, 336823, 352792; KHP: 272376, 266286, 314383, 335443), the Wellcome Trust Sanger Institute (JK), the Broad Institute (JK), ENGAGE – European Network for Genetic and Genomic Epidemiology (JK: FP7-HEALTH-F4-2007, 201413), Finnish Medical Foundation (KHP), Finnish Diabetes Research Foundation (KHP), Novo Nordisk Foundation (KHP: NNF10OC1013354, NNF17OC0027232, and NNF20OC0060547), Gyllenberg Foundation (KHP), Sigrid Juselius Foundation (JK and KHP), Helsinki University Hospital Research Funds (KHP), Jalmari and Rauha Ahokas Foundation (KHP), Finnish Foundation for Cardiovascular Research (KHP), Government Research Funds (KHP), Helsinki University Hospital (KHP), and the University of Helsinki (KHP).
Disclosure: The authors declared no conflict of interest.
Data Availability
The twin dataset used in the current study will be located in the Biobank of the Finnish Institute for Health and Welfare, Finland. All the biobanked data are publicly available for use by qualified researchers following a standardized application procedure (https://thl.fi/en/web/thl-biobank/for-researchers).
